Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation

Ohad Benjamini, MD, Uri Rozovski, MD, Preetesh Jain, MD, DM, PhD, William G. Wierda, MD, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Elizabeth J Shpall, MD, Chitra M Hosing, MD, Issa F. Khouri, MD, Richard E Champlin, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 2880.

https://doi.org/10.1182/blood.V122.21.2880.2880

Published: 2013

Journal Articles

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Preetesh Jain, MD, DM, PhD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Luis Fayad, MD, Jorge Romaguera, MD, Rebecca Garris, BSc, Farhad Ravandi, MD, Susan O'Brien, MD, Deborah Thomas, MD

Blood (2013) 122 (21): 3917.

https://doi.org/10.1182/blood.V122.21.3917.3917

Published: 2013

Journal Articles

Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Preetesh Jain, MD, DM, PhD, Elias Jabbour, MD, Srdan Verstovsek, MD, PhD, Naveen Pemmaraju, MD, Stefan Faderl, MD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD, Carla Tuttle, RN, Mark Brandt, Xuemei Wang, MS, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 5011.

https://doi.org/10.1182/blood.V122.21.5011.5011

Published: 2013

Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD

Blood (2013) 122 (21): 2734.

https://doi.org/10.1182/blood.V122.21.2734.2734

Published: 2013

Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2727.

https://doi.org/10.1182/blood.V122.21.2727.2727

Published: 2013

Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2728.

https://doi.org/10.1182/blood.V122.21.2728.2728

Published: 2013

Journal Articles

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Preetesh Jain, MD, DM, PhD, Hagop Kantarjian, MD, Keyur P. Patel, MD, PhD, Elias Jabbour, MD, Naval Daver, MD, Sherry Pierce, Ohad Benjamini, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Stefan H. Faderl, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2013) 122 (21): 5231.

https://doi.org/10.1182/blood.V122.21.5231.5231

Published: 2013

Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4019.

https://doi.org/10.1182/blood.V122.21.4019.4019

Published: 2013

Journal Articles

Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Tapan M. Kadia, M.D., Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Jorge E. Cortes, MD, Naval Daver, MD, Elias J. Jabbour, MD, Charles Asa Koller, Marina Konopleva, MD, PhD, Naveen Pemmaraju, M.D., Marry A Kelly, Rebecca Garris, BSc, Susan O'Brien, Stefan Faderl, MD

Blood (2012) 120 (21): 1501.

https://doi.org/10.1182/blood.V120.21.1501.1501

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Ohad Benjamini, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Elias Jabbour, MD, Susan O'Brien, M.D., Preetesh Jain, MD, DM, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3783.

https://doi.org/10.1182/blood.V120.21.3783.3783

Published: 2012

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Preetesh Jain, MD, DM, PhD, Long Xuan Trinh, Ohad Benjamini, MD, Susan Lerner, MS, Xuemei Wang, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Zeev Estrov, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Lynne V. Abruzzo, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 2890.

https://doi.org/10.1182/blood.V120.21.2890.2890

Published: 2012

Journal Articles

Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, MD, Ohad Benjamini, MD, Sherry A. Pierce, RN, BS, Marylou Cardenas-Turanzas, Srdan Verstovsek, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 70.

https://doi.org/10.1182/blood.V120.21.70.70

Published: 2012

Journal Articles

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Keyur P. Patel, MD, PhD, Guillermo Garcia Manero, Ohad Benjamini, MD, Gautam Borthakur, M.D., Naveen Pemmaraju, M.D., Tapan M. Kadia, M.D., Naval G. Daver, MD, Aziz Nazha, Rajyalakshmi Luthra, PhD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2484.

https://doi.org/10.1182/blood.V120.21.2484.2484

Published: 2012

NARROW

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML)

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only